Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RepliCel Life Sciences Inc. (REPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.07310.0000 (0.00%)
At close: 09:30AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0731
Open0.0731
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0731 - 0.0731
52 Week Range0.0560 - 0.3200
Volume500
Avg. Volume3,117
Market Cap2.855M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for REPCF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • REPLICEL LIFE SCIENCES INC
    Analyst Report: Abbott LaboratoriesAbbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
    Rating
    Fair Value
    Economic Moat
    8 months agoMorningstar
View more
  • ACCESSWIRE

    RepliCel Announces Material Patent Milestones in Key Markets

    RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as cell-based regenerative medicine products in aesthetics and orthopedics, is pleased to announce the granting of several patents covering novel aspects of the DermaPrecise™ product portfolio, as well as the granting and/or allowance of four other patent applications for its skin rejuvenation

  • ACCESSWIRE

    DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

    RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has received test results showing that cells injected through the DermaPrecise™ Injector maintained >99% viability.

  • ACCESSWIRE

    RepliCel’s Manufacturing Inspected by Japan’s PMDA

    RepliCel Life Sciences Inc. (OTCPINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the completion, last week, of an inspection of RepliCel's NBDS cell therapy manufacturing at its Austrian contract manufacturing facility owned and operated by Innovacell KK (Tokyo, Japan).

Advertisement
Advertisement